knowledge -WSS

knowledge

author：comprehensive 2025-10-01 17:19:19 - browse：388

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Biogen’s boardroom scandal saddles CEO with first crisis

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

Indictment alleges Trump's ex

Health AI: on the border between health care and tech

Exact Sciences stock tumbles despite strong cancer detection sales

Cue Health's Covid

Orangutan used medicinal plant to treat wound, first time ever seen

hotspot

knowledge

focus

Moonlake's readout produced a cash windfall. Risks remain

Cell therapy fails to slow type 1 diabetes, but safety is established

What does generative AI mean for health care? We asked experts

Exact Sciences stock tumbles despite strong cancer detection sales

Jerome Adams on the need for new antivirals for Covid

Dozens dead from Maui wildfires: What we know about the victims

Virginia high school admissions case could be legal follow

After traumatic brain injury, life support decisions can use more time

Activists slam private health insurers over coverage restrictions

More tobacco lobbyists active in statehouses

Wikipedia

Maui wildfire now ranks as the fifth

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

More tobacco lobbyists active in statehouses

Getting Alzheimer's drug Leqembi to patients can be a challenge

Hospitals are dialing back on venture capital investing

Exact Sciences stock tumbles despite strong cancer detection sales

focus

focus

focus

explore